Duloxetine Capsule, Delayed Release
Product Images NDC 68001-595

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68001-595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Dr 20mg 60 Count Paithan (Duloxetine 20mg)

Duloxetine Delayed-Release Capsules label showing 20 mg strength, in a pack of 60 capsules. Label includes directions about dosage, storage, and manufacturer details. Manufactured by Ajanta Pharma Limited, Indian origin, distributed by BluePoint Laboratories. The label features NDC 68001-594-06 and a barcode, indicating Rx only prescription status.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve charting the proportion of patients with relapse over time in days from randomization for Duloxetine compared to placebo. The graph shows relapse proportions on the vertical axis and time to relapse in days on the horizontal axis, with a line for Duloxetine and a separate line for placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis displays ranges of percent pain improvement, and the y-axis shows the percentage of patients improved. Duloxetine is represented with a solid line and placebo with a dashed line.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A survival curve graph depicting the proportion of patients with relapse over time from randomization to relapse in days. The graph compares two treatments: placebo (dashed line) and duloxetine (solid line), showing a lower proportion of relapse in patients treated with duloxetine over approximately 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. Each treatment group is represented by a distinct line, showing trends in patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved at different levels of percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating the relationship between pain improvement and patient response rates over different thresholds of pain improvement.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine capsules at 20 mg, 60 mg, and 120 mg once daily doses with a placebo, illustrating patient response rates across varying levels of pain improvement.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo groups. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved up to 100%. The graph displays two trend lines representing the treatment and placebo responses.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%, with two vertical dashed lines at 30% and 50% improvement.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of Duloxetine hydrochloride, showing the molecular connectivity including a naphthalene moiety, a thiophene ring, and an amine group with attached hydrochloride.*

FDA Label Image

Duloxetine Dr Capsules 20mg 60 Count Bharuch Site (Image 02)

Label for Duloxetine Delayed-Release Capsules 20 mg by BluePoint Laboratories. The label includes dosage form, strength, quantity (60 capsules), NDC number 68001-594-06, and manufacturer details (Ajanta Pharma Limited). Storage and usage instructions, pharmacist dispensing advice, and a barcode are also present.*

FDA Label Image

Duloxetine Dr Capsules 30mg 30 Count Paithan (Image 03)

Label for Duloxetine Delayed-Release Capsules, 30 mg strength, supplied in a 30-capsule package. The label includes instructions to dispense the medication guide, storage conditions, manufacturer information (Ajanta Pharma Limited), and a barcode. The product is labeled for BluePoint Laboratories and indicates Rx only status.*

FDA Label Image

Duloxetine Dr Cap 30mg 30 Count Bharuch Site (Image 04)

Label for Duloxetine Delayed-Release Capsules, 30 mg strength, in a 30-capsule package. The label shows the active ingredient Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine per capsule, with instructions for dispensing by pharmacists. Manufactured by Ajanta Pharma Limited for BluePoint Laboratories, the label includes storage instructions and a barcode.*

FDA Label Image

Duloxetine Dr Capsules 40mg 30 Count Paithan (Image 05)

Label for Duloxetine Delayed-Release Capsules, 40 mg strength, by BluePoint Laboratories. The label states the product is prescription-only, contains 30 capsules, and is manufactured by Ajanta Pharma Limited in India. It includes usage instructions, storage conditions, and a barcode.*

FDA Label Image

Duloxetine Dr Capsules 40mg 30 Count Bharuch Site (Image 06)

Label for Duloxetine Delayed-Release Capsules 40 mg by BluePoint Laboratories, containing 30 capsules. The label includes dosage form and strength, NDC code 68001-570-04, manufacturer Ajanta Pharma Limited, storage instructions, and a barcode. It indicates Rx only and has instructions for the pharmacist to dispense the Medication Guide.*

FDA Label Image

Duloxetine Dr Cap 60mg 30 Count Paithan (Image 07)

Duloxetine Delayed-Release Capsules 60 mg label for BluePoint Laboratories. The label states the capsules contain enteric-coated pellets equivalent to 60 mg Duloxetine. It includes dosage instructions reference, storage conditions, manufacturer details (Ajanta Pharma Limited, India), and package size of 30 capsules. The label also shows a barcode and indicates prescription use only.*

FDA Label Image

Duloxetine Dr Capsules 60mg 30 Count Bharuch Site (Image 08)

Duloxetine Delayed-Release Capsules 60 mg label from BluePoint Laboratories. The label includes dosage form, strength, quantity (30 capsules), manufacturer Ajanta Pharma Limited, and storage instructions. It also features a barcode, a pharmacist instruction, and a note about capsule content and handling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.